

Analysis of Healthcare Professional Management of Immune-Related Adverse Events and Concordance With NCCN Guidelines

Kristen M. Rosenthal, PhD¹; Megan Cartwright, PhD¹; Rachael M. Andrie, PhD¹; John A. Thompson, MD²

1. Clinical Care Options, LLC, Reston, VA.
2. University of Washington, Fred Hutchinson Cancer Center, Seattle, WA.
Contact: mcartwright@clinicaloptions.com

Background

- Immune checkpoint inhibitors (ICIs) are a mainstay of treatment for many cancers¹
- ICIs can cause immune-related adverse events (irAEs) that require prompt recognition and care¹
- In 2017, we developed an online Interactive Decision Support Tool (IDST) for healthcare professionals (HCPs) with case-specific recommendations for managing irAEs from a medical oncology expert²
- In 2019 and 2023, we updated the IDST to offer recommendations from the latest NCCN guidelines^{3,4}

Aims

- To identify **ongoing educational needs** based on **concordance in self-reported irAE management** between HCPs and guideline recommendations in the 2023 IDST
- To evaluate **changes in practice patterns** between the 2023 and 2019 versions of the IDST

Methods

- An online IDST was developed to provide **recommendations on irAE management from NCCN guidelines**
- HCPs entered the **affected organ system, symptom grade/severity**, and their **planned management strategy** before being shown recommendations
- Questions were asked to assess **change in planned management** based on the recommendations shown

Conclusions

- Approximately one half of HCPs who care for patients experiencing irAEs are **not managing irAEs consistent with NCCN guidelines**
- Concordance was lower** for irAEs affecting the **dermatologic/oral mucosa** and **musculoskeletal systems**
- Use of **an online IDST can enhance** HCP management of irAEs to **improve patient outcomes**

References

1. Johnson. Nat Rev Clin Oncol. 2022;19:254.
2. Marcello. SITC 2017. Abstr O33.
3. Cartwright. SITC 2019. Abstr P724.
4. NCCN. Clinical practice guidelines in oncology: management of immunotherapy-related toxicities. v.2.2023.

Supported by educational grants from AstraZeneca, Eisai, Merck Sharp & Dohme LLC, and Regeneron Pharmaceuticals, Inc.

Concordance Between HCPs and NCCN Guidelines Varied by Organ System Affected in 2023

Figure 1. HCP concordance with NCCN guidelines in managing irAEs by primary affected organ system in 2023.




Figure 2. Impact of IDST on HCP management plan and patients in 2023.





Figure 3. 172 HCPs entered 241 cases in the online IDST in 2023.

- 75% of HCPs were physicians, and 64% specialized in oncology/hematology
- HCPs practiced in the United States (38%), Europe (21%), and rest of world (41%)
- 47% of HCPs reported treating ≥ 10 patients/month with ICIs
- The most common organ systems affected by irAEs entered into the online IDST were GI/hepatobiliary/pancreatic (29%) and dermatologic/oral mucosa (19%)






Figure 4. HCP concordance with NCCN guidelines by severity of irAE in 2023.



- Among the irAE cases entered, 30% were severe/life threatening
- HCP concordance with NCCN guidelines was slightly lower for severe/life-threatening vs mild/moderate irAEs

Figure 5. Change in HCP concordance with NCCN guidelines in managing irAEs from 2019 to 2023.



- HCP concordance with NCCN guidelines in managing irAEs increased from 2019 to 2023